FIELD: medicine.
SUBSTANCE: group of inventions relates to the methods of determining the risk of developing dementia in a subject who does not suffer from dementia and to the use of antibodies to adrenomedullin (ADM) for the prevention and treatment of dementia. The following is determined: the level of mature ADM-NH2 according to SEQ ID No. 4 in a subject's body fluid sample or a marker ratio, which may be a mature ADM-NH2 level ratio according to SEQ ID No. 4 to the level of pro-adrenomedullin or a fragment thereof, which is immature ADM-NH2 according to SEQ ID No. 4. The mature ADM-NH2 level or marker ratio is compared with a threshold level. The subject is at increased risk of developing dementia if the mature ADM-NH2 level of SEQ ID No. 4 or the mature ADM-NH2/pro-adrenomedullin marker ratio is below the threshold level/ratio.
EFFECT: group of inventions ensures the determination of the risk of developing dementia.
13 cl, 8 dwg, 5 tbl, 7 ex
